Suberoylanilide Hydroxamic Acid (SAHA) is a potent histone deacetylase (HDAC) inhibitor that has been shown to inhibit proliferation and cause cell cycle arrest at G1. Experiments suggest that SAHA also causes morphological changes, such as enlargement and flattening of the cytoplasm, resulting in growth inhibition. Treatment of cells with SAHA also decreases the expression of anti-apoptosis proteins Bcl-xL and survivin.

A potent HDAC inhibitor; also causes cell cycle arrest at G1

SAHA可用于研究基因调控、转录调控和细胞信号转导。

Information

In vitro

Vorinostat inhibits the activities of HDAC1 and HDAC3 with IC50 of 10 nM and 20 nM, respectively. Vorinostat also results in a marked hyperacetylation of histone H4. Vorinostat inhibits the growth of three prostate cancer cell lines LNCaP, PC-3 and TSU-Pr1 at micromolar concentrations (2.5-7.5 μM), and induces dose-dependent cell death in LNCaP cells. Vorinostat treatment in MCF-7 cells inhibits cell proliferation at an IC50 of 0.75 μM resulting in the accumulation of cells in the G1 and G2-M phase of the cell cycle. Vorinostat also induces differentiation in the estrogen receptor-negative cell line SKBr-3 and the retinoblastoma-negative cell line MDA-468. Vorinostat treatment at 1 μM for 8 hours or more is sufficient to irreversibly induce apoptosis of human multiple myeloma (MM) cells. The gene expression profiles of Vorinostat treated MM cells are not hallmarked by global transcriptional activation, but by coordinated transcriptional changes of specific functional groups of genes such as cytokine-induced proliferative/survival signaling cascades, oncogenes-tumor suppressor genes, regulators of apoptosis, DNA synthesis-repair and cell cycle, and proteasome-ubiquitin function.

In vivo

Administration of Vorinostat (~100 mg/kg/day) significantly inhibits the growth of CWR22 human prostate xenografts in nude mice with tumor reductions of 78%, 97% and 97%, at doses of 25 mg/kg/day, 50 mg/kg/day and 100 mg/kg/day, respectively, compared with control. Vorinostat induces the accumulation of acetylated core histones and prostate-specific antigen mRNA expression in CWR22 cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. Oral administration of Vorinostat (0.67g/L) crosses the blood-brain barrier, increases histone acetylation in the brain, and dramatically improves the motor impairment in the R6/2 mice model of Huntington\'s disease.
Cell Data

cell lines：

Concentrations：Dissolved in DMSO, final concentrations ~7.5 μM

Incubation Time：1, 2, 3 and 4 days

Powder Purity:≥99%

规格

英文别名

MK0683, Suberoylanilide hydroxamic acid

规格或纯度

Moligand™, 10mM in DMSO

英文名称

Vorinostat (SAHA)

生化机理

Vorinostat（suberoylanilide hydroxamic acid，SAHA，MK0683）是一种 HDAC 抑制剂，在无细胞试验中的 IC50 值约为 10 nM。伏立诺他能抑制 HPV-18 DNA 的生产性扩增。

储存条件

-80℃储存

运输条件

特低温运输

作用类型

抑制剂

作用机制

组蛋白去乙酰化酶 2 抑制剂

名称和识别符

EC号

682-505-1

分子类型

小分子

Isomeric SMILES

C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO

PubChem CID

5311

分子量

264.32

技术文档

📋 安全数据表 (SDS)

全面的危险、操作、储存及法规合规文件。

下载 SDS →

✅ 分析证书 (COA)

批次质量数据。输入批号以获取对应 COA。

查询 COA →

📊 产品数据表

产品规格和应用的快速参考摘要。

查看数据表 →

🔬 规格说明书

该级别的完整质量属性和验收标准。

查看规格说明 →

高级数据

产品属性

ALogP	1.9

关联靶点（人）

BRD4 Tchem 含溴结构域蛋白 4(Bromodomain-containing protein 4) (2 活性数据)

点击查看靶蛋白信息： BRD4

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

HDAC4 Tclin 组蛋白去乙酰化酶4(Histone deacetylase 4) (19 活性数据)

点击查看靶蛋白信息： HDAC4

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

HDAC6 Tclin 组蛋白去乙酰化酶6(Histone deacetylase 6) (236 活性数据)

点击查看靶蛋白信息： HDAC6

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

HDAC1 Tclin 组蛋白去乙酰化酶1(Histone deacetylase 1) (272 活性数据)

点击查看靶蛋白信息： HDAC1

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

HDAC7 Tclin 组蛋白去乙酰化酶7(Histone deacetylase 7) (10 活性数据)

点击查看靶蛋白信息： HDAC7

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

HDAC11 Tclin 组蛋白去乙酰化酶11(Histone deacetylase 11) (25 活性数据)

点击查看靶蛋白信息： HDAC11

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

HDAC9 Tclin 组蛋白去乙酰化酶9(Histone deacetylase 9) (11 活性数据)

点击查看靶蛋白信息： HDAC9

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

HDAC2 Tclin 组蛋白去乙酰化酶2(Histone deacetylase 2) (154 活性数据)

点击查看靶蛋白信息： HDAC2

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

HDAC10 Tclin 组蛋白去乙酰化酶10(Histone deacetylase 10) (42 活性数据)

点击查看靶蛋白信息： HDAC10

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

HDAC8 Tclin 组蛋白去乙酰化酶8(Histone deacetylase 8) (83 活性数据)

点击查看靶蛋白信息： HDAC8

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

HDAC5 Tclin 组蛋白去乙酰化酶5(Histone deacetylase 5) (12 活性数据)

点击查看靶蛋白信息： HDAC5

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

HDAC3 Tclin 组蛋白去乙酰化酶3(Histone deacetylase 3) (111 活性数据)

点击查看靶蛋白信息： HDAC3

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

KCNH2 Tclin 钾电压门控通道亚家族 H 成员 2(Potassium voltage-gated channel subfamily H member 2) (1 活性数据)

点击查看靶蛋白信息： KCNH2

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

化学和物理性质

溶解性

Solubility (25°C) In vitro DMSO: 100 mg/mL (85.2 mM); Ethanol: 100 mg/mL (85.2 mM); Water: Insoluble;

熔点

155 °C

安全和危险性（GHS）

象形图

GHS08, GHS09, GHS07

信号词

Danger

危险声明

H341: 怀疑引起遗传缺陷

H302: 吞食有害

H400: 对水生生物有剧毒

H410: 对水生生物有剧毒并具有长期持续影响

H372: 通过长时间或反复暴露对器官造成损害

H360: 可能损害生育力或未出生的孩子

预防措施声明

P273: 避免释放到环境中。

P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。

P405: 密闭存放

P501: 将内容物/容器处理到。。。

P264: 处理后要彻底洗手。

P260: 不要吸入灰尘/烟雾/气体/雾/蒸汽/喷雾。

P281: 根据需要使用个人防护设备。

P270: 使用本产品时，请勿进食、饮水或吸烟。

P391: 收集溢出物

P330: 漱口

P203: 使用前，获取、阅读并遵守所有安全说明。

P301+P317: 如果被吞咽：请寻求医疗帮助。

P318: 如果暴露或担心，请就医。

P319: 如果你感到不适，请寻求医疗帮助。

WGK Germany

Merck Index

10034

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到1个结果

批号(Lot Number)	证书类型	货号
A2305009	分析证书	V407894

技术文档和文章

表观遗传调控剂

目录：技术文章

探索主题:

极光激酶表观遗传学 DNMTs 组蛋白甲基转移酶抑制剂 HDACs

Epigenetic Modifiers

目录：技术文章

探索主题:

Aurora Kinases DNMTs HDACs Epigenetics Histone Methyltransferase Inhibitors

组蛋白去乙酰化酶抑制剂

目录：技术文章

探索主题:

HDAC抑制剂

Histone Deacetylase Inhibitors

目录：技术文章

探索主题:

HDAC inhibitors

PROTAC设计三要素：E3连接酶配体、Linker与靶蛋白配体（附阿拉丁试剂选型指南）

目录：技术文章

探索主题:

靶向蛋白降解 PROTAC 杂合双功能小分子化合物

Three Key Components of PROTAC Design: E3 Ligase Ligands, Linkers, and Target Protein Ligands (with an Aladdin Reagent Selection Guide)

目录：技术文章

探索主题:

PROTAC Protein degradation Hybrid bifunctional small molecule compound

小分子抑制剂科研选型指南：最小证据链与场景化验证框架（含选型矩阵、案例卡片与产品表1–表4）

目录：技术文章

探索主题:

小分子抑制剂

Small-Molecule Inhibitors: A Practical Guide for Research Selection — A Minimal Evidence Chain and Scenario-Based Validation Framework (Including a Selection Matrix, Case Cards, and Product Tables 1–4)

目录：技术文章

探索主题:

Small-Molecule Inhibitors

乙酰基代谢酶网络与体外酶学分析

目录：技术文章

探索主题:

去乙酰化酶表观调控乙酰基代谢乙酰辅酶A 乙酰转移酶通路解析体外酶学中心碳代谢

Acetyl-Group Metabolic Enzyme Network and In Vitro Enzymology Analysis

目录：技术文章

探索主题:

Epigenetic Regulation Acetyl-Group Metabolism Acetyl-Coa Acetyltransferases Deacetylases Pathway Analysis In Vitro Enzymology Central Carbon Metabolism

表观遗传酶的非经典功能与线粒体代谢调控

目录：技术文章

探索主题:

表观遗传酶非经典功能线粒体代谢 mtDNA 线粒体蛋白乙酰化 DNMT1 MOF LSD1

Noncanonical Functions of Epigenetic Enzymes and Regulation of Mitochondrial Metabolism

目录：技术文章

探索主题:

mtDNA DNMT1 MOF LSD1 epigenetic enzymes noncanonical functions mitochondrial metabolism mitochondrial protein acetylation

三维染色质结构重塑与生理性衰老机制

目录：技术文章

探索主题:

三维染色质生理性衰老 A/B区室拓扑相关结构域染色质环核纤层相关结构域异染色质

Three-Dimensional Chromatin Architecture Remodeling and Mechanisms of Physiological Aging

目录：技术文章

探索主题:

three-dimensional chromatin physiological aging A/B compartments topologically associating domains chromatin loops lamina-associated domains heterochromatin

DNA 序列不变，基因表达为何改变？表观遗传调控的核心机制与研究方法

目录：技术文章

探索主题:

DNA 基因表达表观遗传

If the DNA Sequence Remains Unchanged, Why Does Gene Expression Change? Core Mechanisms and Research Methods of Epigenetic Regulation

目录：技术文章

探索主题:

DNA Epigenetics gene expression

蛋白质翻译后修饰的调控机制、研究方法与修饰组学分析

目录：技术文章

探索主题:

糖基化质谱分析甲基化蛋白质翻译后修饰泛素化 SUMO化磷酸化乙酰化乳酸化修饰蛋白质组学

Regulatory Mechanisms, Research Methods, and Modification-Omics Analysis of Protein Post-Translational Modifications

目录：技术文章

探索主题:

Glycosylation methylation SUMOylation Protein Post-Translational Modifications Ubiquitination Phosphorylation Acetylation Lactylation Modification Proteomics

此产品的引用文献

如何在您的发表作品中引用阿拉丁的产品和网站? 引用文献检索

引用文献

1. Lei Hou, Yunchang Zhang, Ying Huang, Zhen Fang, Guangze Sang, Tianheng Chen, Zhiqiang Ma, Feng Yang. (2022) Coupling Chlorin-Based Photosensitizers and Histone Deacetylase Inhibitors for Photodynamic Chemotherapy. MOLECULAR PHARMACEUTICS, [PMID:35758904] [10.1021/acs.molpharmaceut.2c00170]
2. Jia Man, Xiaojie Wang, Jianyong Li, Xiaoyang Cui, Zesheng Hua, Jianfeng Li, Zebing Mao, Shanguo Zhang. (2022) Intravenous Calcium Alginate Microspheres as Drug Delivery Vehicles in Acute Kidney Injury Treatment. Micromachines, 13 (4): (538). [PMID:35457843] [10.3390/mi13040538]
3. Yingjie Yu, Bingkai Wang, Miao Sun, Yunchang Zhang, Lei Hou, Sizhen Wang, Tianheng Chen, Feng Yang, Zhiqiang Ma. (2022) Lysosomal activable Vorinostat carrier-prodrug self-assembling with BPQDs enables photothermal oncotherapy to reverse tumor thermotolerance and metastasis. INTERNATIONAL JOURNAL OF PHARMACEUTICS, [PMID:35202725] [10.1016/j.ijpharm.2022.121580]
4. Miao Jiefei, Meng Chi, Wu Hongmei, Shan Wenpei, Wang Haoran, Ling Changchun, Zhang Jinlin, Yang Tao. (2021) Novel Hybrid CHC from β-carboline and N-Hydroxyacrylamide Overcomes Drug-Resistant Hepatocellular Carcinoma by Promoting Apoptosis, DNA Damage, and Cell Cycle Arrest. Frontiers in Pharmacology, [PMID:33536926] [10.3389/fphar.2020.626065]
5. Shanguo Zhang, Xiaojie Wang, Jia Man, Jianyong Li, Xiaoyang Cui, Chuanwei Zhang, Weichen Shi, Donghai Li, Song Zhang, Jianfeng Li. (2020) Histone Deacetylase Inhibitor-loaded Calcium Alginate Microspheres for Acute Kidney Injury Treatment. ACS Applied Bio Materials, [PMID:35021777] [10.1021/acsabm.0c00874]
6. Qian Zhu, Lixin Jia, Zhongfei Gao, Chunming Wang, Haoyang Jiang, Junfeng Zhang, Lei Dong. (2014) A Tumor Environment Responsive Doxorubicin-Loaded Nanoparticle for Targeted Cancer Therapy. MOLECULAR PHARMACEUTICS, [PMID:24735448] [10.1021/mp4007776]
7. Weiwei Jiang, Yuwei Cheng, Lei Hou, Ying Huang, Sizhen Wang, Yunchang Zhang, Tao Jiang, Feng Yang, Zhiqiang Ma. (2024) A dual-prodrug nanogel combining Vorinostat and Pyropheophorbide a for a high efficient photochemotherapy. INTERNATIONAL JOURNAL OF PHARMACEUTICS, [PMID:38977163] [10.1016/j.ijpharm.2024.124422]
8. Penghui Du, Wen Liu, Qiang Zhang, Peng Zhang, Chen He, Quan Shi, Ching-Hua Huang, Junjian Wang. (2023) Transformation of dissolved organic matter during UV/peracetic acid treatment. WATER RESEARCH, [PMID:36738558] [10.1016/j.watres.2023.119676]
9. Yaowei Guo, Jin Liu, Qinglin Tang, Cuicui Li, Yanying Zhang, Yao Wang, Yanxin Wang, Yupeng Bi, Christopher D. Snow, Matt J. Kipper, Laurence A. Belfiore, Jianguo Tang. (2022) Lanthanide (Eu3+/Tb3+)-Loaded γ-Cyclodextrin Nano-Aggregates for Smart Sensing of the Anticancer Drug Irinotecan. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 23 (12): (6597). [PMID:35743042] [10.3390/ijms23126597]
10. Yue Wei, Si Wu, Zhenqi Liu, Jingsheng Niu, Ya Zhou, Jinsong Ren, Xiaogang Qu. (2022) Tumor associated macrophages reprogrammed by targeted bifunctional bioorthogonal nanozymes for enhanced tumor immunotherapy. Materials Today, [10.1016/j.mattod.2022.01.024]
11. Rui Li, Li Xie, Lei Li, Xiaojiao Chen, Tong Yao, Yuanxin Tian, Qingping Li, Kai Wang, Chenyang Huang, Cui Li, Yifan Li, Hongwei Zhou, Neil Kaplowitz, Yong Jiang, Peng Chen. (2021) The gut microbial metabolite, 3,4-dihydroxyphenylpropionic acid, alleviates hepatic ischemia/reperfusion injury via mitigation of macrophage pro-inflammatory activity in mice. Acta Pharmaceutica Sinica B, [PMID:35127379] [10.1016/j.apsb.2021.05.029]
12. Pisano S., Wang X., Garcia-Parra J., Gazze A., Edwards K., Feltracco V., Hu Y., He L., Gonzalez D., Francis L. W., Conlan R. S., Li C.. (2020) Nanomicelles potentiate histone deacetylase inhibitor efficacy in vitro. Cancer Nanotechnology, 11 (1): (1-17). [10.1186/s12645-020-00070-8]
13. Xie Qiu-shi, Zhang Jia-xin, Liu Ming, Liu Pei-hua, Wang Zhong-jian, Zhu Liang, Jiang Ling, Jin Meng-meng, Liu Xiao-nan, Liu Li, Liu Xiao-dong. (2020) Short-chain fatty acids exert opposite effects on the expression and function of p-glycoprotein and breast cancer resistance protein in rat intestine. ACTA PHARMACOLOGICA SINICA, 42 (3): (470-481). [PMID:32555444] [10.1038/s41401-020-0402-x]
14. Zhihong Yao, Shishi Li, Zifei Qin, Xiaodan Hong, Yi Dai, Baojian Wu, Wencai Ye, Frank J. Gonzalez, Xinsheng Yao. (2017) Characterization of human UDP-glucuronosyltransferases responsible for glucuronidation and inhibition of norbakuchinic acid, a primary metabolite of hepatotoxicity and nephrotoxicity component bakuchiol in Psoralea corylifolia L.. RSC Advances, 7 (83): (52661-52671). [10.1039/C7RA10376J]
15. Dong Shanshan, Li Mu, Chen Yinguang. (2017) Inherent humic substance promotes microbial denitrification of landfill leachate via shifting bacterial community, improving enzyme activity and up-regulating gene. Scientific Reports, 7 (1): (1-10). [PMID:28939832] [10.1038/s41598-017-12565-3]
16. Xiao-Li Zheng, Zhi-Di Li, Kai-Zhi Luo, Yang-Ling Li, Ye-Han Liu, Shu-Ying Shen, Fei-Yan Shen, Wan-Yan Li, Guo-Qing Chen, Chong Zhang, Ling-Hui Zeng. (2024) POLR2J expression promotes glioblastoma malignancy by regulating oxidative stress and the STAT3 signaling pathway. American Journal of Cancer Research, [PMID:38859843] [10.62347/JEWM7691]
17. Lu Hui, Fu Wenying, Xia Yiqun, Yan Ying, Shu Chongchong, Chen Yinghua, Xu Chenxin, Zheng Peisen, Shen Xin, Cui Ri, Zou Peng, Ni Daoyong. (2025) Panobinostat potentiates adagrasib-induced cell death by triggering autophagy in human non-small cell lung cancer. Cell Death Discovery, 11 (1): (1-16). [PMID:40750601] [10.1038/s41420-025-02657-9]
18. Yanhong Guo, Shuhao Xu, Xue Guo, Jing Xu, Zhenyu Li, Ying Wang, Zhenhao Li, Zheyong Xue. (2026) Synergistic effects of exogenous inducers on ganoderic acid accumulation in Ganoderma lucidum: optimization and transcriptomic analysis. Medicinal Plant Biology, 5 (1): [10.48130/mpb-0025-0039]